Parallel Advisors
CRNX icon

Parallel Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Parallel Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-913
Closed -$34.2K – 4066
2026
Q2 		$34.2K Hold
913
– – ﹤0.01% 2372
2026
Q1 		$33.2K Sell
913
-312
-25% -$13.9K ﹤0.01% 2225
2025
Q4 		$57K Buy
1,225
+315
+35% +$14K ﹤0.01% 1778
2025
Q3 		$37.9K Sell
910
-87
-9% -$2.78K ﹤0.01% 1930
2025
Q2 		$28.7K Sell
997
-552
-36% -$17K ﹤0.01% 2021
2025
Q1 		$52K Buy
1,549
+50
+3% +$1.87K ﹤0.01% 1617
2024
Q4 		$76.6K Buy
1,499
+10
+0.7% +$559 ﹤0.01% 1403
2024
Q3 		$76.1K Hold
1,489
– – ﹤0.01% 1397
2024
Q2 		$66.7K Sell
1,489
-63
-4% -$2.91K ﹤0.01% 1374
2024
Q1 		$72.6K Buy
1,552
+1,113
+254% +$43.5K ﹤0.01% 1317
2023
Q4 		$15.6K Buy
+439
New +$13.5K ﹤0.01% 2089
2022
Q4 		– Sell
-6
Closed – – 3383
2022
Q3 		$0 Buy
+6
New +$122 ﹤0.01% 3194
2021
Q4 		– Sell
-6
Closed – – 3115
2021
Q3 		$0 Buy
+6
New +$126 ﹤0.01% 3096

Other funds holding CRNX

IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Allworth Financial
Allworth Financial Folsom, California $28.2B AUM 13.34% 1-Year Est. Return

Parallel Advisors's CRNX Position: Q3 2026 in Review

Parallel Advisors sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2026, closing a stake of 913 shares — an estimated $34.2K sold.

Parallel Advisors first reported a position in CRNX in Q3 2021 and held it in 13 quarters. The position peaked at $76.6K in Q4 2024. 2 funds tracked by Wall St. Rank hold CRNX as of Q3 2026.

  • Parallel Advisors reported no remaining Crinetics Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Parallel Advisors sold 913 Crinetics Pharmaceuticals shares in Q3 2026, an estimated $34.2K.
  • Parallel Advisors first reported a position in Crinetics Pharmaceuticals in Q3 2021 and held it in 13 quarters.
  • Parallel Advisors's Crinetics Pharmaceuticals position peaked at $76.6K in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.